Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
60.89
-0.43 (-0.70%)
Aug 10, 2026, 4:00 PM EDT - Market closed
Travere Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 591.33 | 490.73 | 233.18 | 145.24 | 109.46 | 131.84 | |
Revenue Growth | 77.12% | 110.45% | 60.55% | 32.69% | -16.97% | -33.52% |
Cost of Revenue | 8.26 | 10.34 | 7.74 | 11.45 | 4.42 | 3.82 |
Gross Profit | 583.07 | 480.39 | 225.43 | 133.79 | 105.04 | 128.02 |
Selling, General & Admin | 364.51 | 337.2 | 264.12 | 265.54 | 197.52 | 126.28 |
Research & Development | 227.14 | 206.01 | 217.5 | 244.99 | 227.33 | 201.16 |
Other Operating Expenses | 31.88 | - | 67.64 | 11.39 | - | - |
Total Operating Expenses | 623.53 | 543.21 | 549.26 | 521.93 | 424.85 | 327.44 |
Operating Income | -40.46 | -62.82 | -323.83 | -388.14 | -319.81 | -199.43 |
Interest Income | 11.58 | 12.72 | 17.82 | 21.77 | 6.28 | 1.99 |
Interest Expense | -9.48 | -10.75 | -11.18 | -11.33 | -11.01 | -19.68 |
Other Non-Operating Income (Expense) | -28.71 | 11.58 | -3.32 | 1.59 | -6.6 | 0.23 |
Total Non-Operating Income (Expense) | -26.62 | 13.55 | 3.32 | 12.03 | -11.34 | -17.46 |
Pretax Income | -67.07 | -49.27 | -320.51 | -376.11 | -331.16 | -216.88 |
Provision for Income Taxes | -0.32 | 0.99 | 0.12 | 0.22 | 0.31 | 0.41 |
Net Income | -66.75 | -50.26 | -320.63 | -376.33 | -331.47 | -217.29 |
Earnings From Discontinued Operations | 24.22 | 24.72 | -0.92 | 264.93 | 52.99 | 37.2 |
Net Income to Common | -43.46 | -25.55 | -321.55 | -111.4 | -278.48 | -180.09 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 91 | 89 | 79 | 74 | 64 | 60 |
Shares Outstanding (Diluted) | 95 | 89 | 79 | 74 | 64 | 60 |
Shares Change | 11.85% | 13.08% | 6.22% | 16.48% | 6.56% | 25.86% |
EPS (Basic) | -0.45 | -0.29 | -4.08 | -1.50 | -4.37 | -3.01 |
EPS (Diluted) | -0.46 | -0.29 | -4.08 | -1.50 | -4.37 | -3.01 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | 92.7 | 37.78 | -237.48 | -280.02 | -186.29 | -19.89 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | 0.98 | 0.42 | -3.01 | -3.77 | -2.92 | -0.33 |
Gross Margin | 98.60% | 97.89% | 96.68% | 92.12% | 95.96% | 97.10% |
Operating Margin | -6.84% | -12.80% | -138.88% | -267.24% | -292.17% | -151.27% |
Profit Margin | -11.29% | -10.24% | -137.51% | -259.12% | -302.82% | -164.82% |
FCF Margin | 15.68% | 7.70% | -101.84% | -192.80% | -170.19% | -15.09% |
EBITDA | 22.91 | -2.08 | -280.27 | -349.61 | -299.09 | -186.68 |
EBITDA Margin | 3.87% | -0.42% | -120.20% | -240.71% | -273.25% | -141.60% |
EBIT | -40.46 | -62.82 | -323.83 | -388.14 | -319.81 | -199.43 |
EBIT Margin | -6.84% | -12.80% | -138.88% | -267.24% | -292.17% | -151.27% |
Effective Tax Rate | 0.48% | -2.01% | -0.04% | -0.06% | -0.09% | -0.19% |